0.52 USD
↘ 0.04 (7.84%)AT CLOSE (03:59 PM EDT)
Outlook Therapeutics, Inc. Common Stock
OTLKNASDAQ • USD
0.53
↗ 0.01 (1.48%)
POST MARKET (AS OF 07:49 PM EDT)
Post Market
AS OF 07:49 PM EDT
0.53
↗ 0.01 (1.48%)
Market: CLOSED
Outlook Therapeutics, Inc. Common Stock (OTLK) is currently trading at $0.52. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, exceptional Return on Equity (460.2%), a bullish Golden Cross on the moving averages and bearish long-term moving average alignment.
Technical & fundamental data as of Oct 23, 2026.
Open?$0.56
High?$0.56
Low?$0.51
Prev. Close?$0.56
Volume?3.1M
Avg. Volume?4.3M
VWAP?$0.53
Rel. Volume?0.71x
Bid / Ask
Bid?$0.53 × 500
Ask?$0.53 × 2.4K
Spread?$0.00
Midpoint?$0.53
Valuation & Ratios
Market Cap?126.6M
Shares Out?243.4M
Float?83.0M
Float %?99.9%
P/E Ratio?N/A
P/B Ratio?-12.18
EPS?-$0.20
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Employees
17
Market Cap
126.4M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2016-05-13
Address
111 S. WOOD AVENUE
ISELIN, NJ 08830
Phone: (609) 619-3990
ISELIN, NJ 08830
Phone: (609) 619-3990
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-1/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?12
Z-Score?0
Momentum?29
Short Sent.?36
Piotroski F-Score?2/9Weak
Altman Z-Score?-37.99Distress
Confidence?63%Moderate
Short InterestSqueeze Risk
Short % of Float?38.43%Squeeze Risk
Short Interest?31.9M
Days to Cover?7.1
Free Float83.0M
Avg Daily Volume4.5M
Settlement Date2026-09-30
Financial Health
Current Ratio?0.81Weak
Quick Ratio?0.63Weak
Cash Ratio?0.39Low
Debt/Equity?-1.75Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?-12.18CHEAP▾
S&P97
P/S?-118.12CHEAP▾
S&P97
P/FCF?N/A▾
EV/EBITDA?-3.5CHEAP▾
S&P97
EV/Sales?-124.64CHEAP▾
S&P97
Returns & Efficiency
ROE?460.2%STRONG▾
Peers50
S&P97
ROA?-182.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-56154885
Enterprise Value?$133.6M
Fundamentals ratios updated end of day